Natriuretic Peptide, C-Type
"Natriuretic Peptide, C-Type" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PEPTIDE of 22 amino acids, derived mainly from cells of VASCULAR ENDOTHELIUM. It is also found in the BRAIN, major endocrine glands, and other tissues. It shares structural homology with ATRIAL NATRIURETIC FACTOR. It has vasorelaxant activity thus is important in the regulation of vascular tone and blood flow. Several high molecular weight forms containing the 22 amino acids have been identified.
| Descriptor ID |
D020098
|
| MeSH Number(s) |
D06.472.699.584.750 D12.644.548.585.750
|
| Concept/Terms |
Natriuretic Peptide, C-Type- Natriuretic Peptide, C-Type
- Natriuretic Peptide, C Type
- Peptide, C-Type Natriuretic
- CNP-22
- C-Type Natriuretic Peptide-22
- C Type Natriuretic Peptide 22
- Natriuretic Peptide-22, C-Type
- Peptide-22, C-Type Natriuretic
- C-Type Natriuretic Peptide
- C Type Natriuretic Peptide
CNP-53- CNP-53
- C-Type Natriuretic Peptide-53
- C Type Natriuretic Peptide 53
- Natriuretic Peptide-53, C-Type
- Peptide-53, C-Type Natriuretic
|
Below are MeSH descriptors whose meaning is more general than "Natriuretic Peptide, C-Type".
Below are MeSH descriptors whose meaning is more specific than "Natriuretic Peptide, C-Type".
This graph shows the total number of publications written about "Natriuretic Peptide, C-Type" by people in this website by year, and whether "Natriuretic Peptide, C-Type" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Natriuretic Peptide, C-Type" by people in Profiles.
-
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model. Clin Pharmacokinet. 2024 May; 63(5):707-719.
-
Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2024 01; 8(1):40-50.
-
Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia. Sci Rep. 2021 12 20; 11(1):24278.
-
Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet. 2022 02; 61(2):263-280.
-
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021 12; 23(12):2443-2447.
-
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020 09 05; 396(10252):684-692.
-
C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia. N Engl J Med. 2019 07 04; 381(1):25-35.
-
Atrial-Specific Gene Delivery Using an Adeno-Associated Viral Vector. Circ Res. 2019 01 18; 124(2):256-262.
-
Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trial. CMAJ. 2018 10 29; 190(43):E1273-E1280.
-
Myeloprotective effects of C-type natriuretic peptide on cisplatin-induced bone marrow granulocytopenia in mice. Cancer Chemother Pharmacol. 2017 02; 79(2):363-368.